	Ardian, a private investment company, together with current management, announced on July 22 the acquisition of the Exclusive Synthesis (ES) and Maleic Anhydride Intermediates & Specialties (IM) business activities of DPx Holdings B.V., based in Linz, Austria. Details of the transaction were not disclosed.

	ES develops and produces chemical intermediate products for agriculture and other industries. IM produces maleic anhydride, intermediates, derivatives, and esters. The groups had a combined sales of €200 million for the 2014 financial year and 390 employees.

	With the support of Ardian, the management of ES and IM plans to significantly strengthen its market position, the company reports in a statement. Investment will focus on expanding the product portfolio through organic growth, strategic acquisitions, and expanding into new markets.

	DPx Holdings B.V. is the parent company of the Patheon, DPx Fine Chemicals, and Banner Life Sciences businesses.

API Synthesis and Manufacturing, Small Molecule

Development

Ingredients

PharmTech News

Small-Molecule APIs

Supplier News

PTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015

Investment group Ardian will acquire the fine chemicals business activities of DPx Holdings B.V.